Aligos Therapeutics develops investigational therapies for liver and viral diseases as a clinical-stage biotechnology company. Its news centers on programs for chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections, including pevifoscorvir sodium, ALG-055009, ALG-097558, and ALG-170675.
Recurring updates cover clinical and nonclinical data, regulatory designations, scientific-conference presentations, quarterly financial results, research and development spending, licensing agreements, and equity compensation actions. Company releases also describe the Phase 2 B-SUPREME study of pevifoscorvir sodium, FDA Fast Track Designation for chronic HBV infection, and the exclusive license agreement for Greater China with Xiamen Amoytop Biotech.
Aligos Therapeutics (NASDAQ: ALGS) reported strong financial results for Q4 and the full year 2020, with cash reserves of $243.5 million following a successful IPO raising $167.2 million. The company advanced two drug candidates, ALG-010133 and ALG-000184, into clinical trials for Chronic Hepatitis B (CHB) and expects to generate safety and antiviral activity data in 2021. However, net losses reached $108.5 million for the year, up from $52.3 million in 2019, reflecting increased R&D expenses of $79.9 million.
Aligos Therapeutics (Nasdaq: ALGS) has initiated dosing of its first drug candidate, ALG-010133, in chronic hepatitis B (CHB) patients as part of the ALG-010133-101 study. This proprietary molecule aims to reduce viral S-antigen levels, pivotal for HBV replication. Preclinical studies show promising inhibition of S-antigen. Currently, 72 healthy volunteers have been dosed, indicating an acceptable safety profile. Results from the initial patient cohorts are expected in the second half of 2021. Aligos aims to develop a treatment regimen that may lead to a functional cure for CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced the presentation of its SARS-CoV-2 3CLpro inhibitor candidate, ALG-097111, at the 28th Conference on Retroviruses and Opportunistic Infections. The presentation highlighted in vivo evidence of potent virus inhibition in infected hamsters, achieving a 3.5 log10 reduction in viral RNA. ALG-097111 showed high selectivity with an IC50 of 7 nM, indicating its potential as a targeted therapeutic option amid COVID-19's evolving strains. CEO Lawrence Blatt emphasized its importance for untreated and vaccine-resistant patients.
Aligos Therapeutics (Nasdaq: ALGS) will present four posters at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL) from February 4-6, 2021. The presentations will showcase progress in their chronic hepatitis B (CHB) drug candidates, ALG-010133 and ALG-000184, currently in Phase 1a/b studies. Notable findings include ALG-010133's promising preclinical efficacy and pharmacokinetics, and ALG-000184's safety and tolerability data. These trials aim to develop effective combination therapies against CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence Blatt will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 3:40 PM ET. The presentation will include a virtual Q&A session, with the webcast recording available for 30 days afterward. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, the company aims to lead in antiviral therapies using its extensive drug development expertise.
Aligos Therapeutics (Nasdaq: ALGS) recently presented at the RespiDART & Emerging Viruses 2020 meeting, showcasing advancements in their SARS-CoV-2 therapeutic candidate, ALG-097111. The presentation underscored the development of a multiplex screening platform to identify selective inhibitors for the viral 3CLpro protease, essential for viral replication. ALG-097111 demonstrated significant inhibition without affecting human cathepsin L, highlighting its potential as a targeted treatment for SARS-CoV-2. Collaborations with KU Leuven were pivotal in these developments.
Aligos Therapeutics (Nasdaq: ALGS) announced a collaboration with Merck to leverage its oligonucleotide platform technology for developing therapies targeting non-alcoholic steatohepatitis (NASH) and potentially other conditions. The agreement includes an upfront payment and up to $458M in development milestones along with tiered royalties on sales. Aligos will focus on designing and optimizing oligonucleotides, while Merck will handle clinical development and commercialization. This collaboration aims to address the critical need for effective NASH treatments amidst growing liver disease concerns.
Aligos Therapeutics (Nasdaq: ALGS) presented six posters and one oral presentation at the AASLD Liver Meeting Digital Experience 2020, highlighting advancements in its liver disease programs. Key updates included progress on chronic hepatitis B (CHB) therapies and the nonalcoholic steatohepatitis (NASH) treatment candidate ALG-055009. The company is optimistic about its combination regimens for CHB that may lead to functional cures and has begun Phase 1 trials for two drug candidates, ALG-010133 and ALG-000184, aimed at CHB.
Aligos Therapeutics (Nasdaq: ALGS) announced participation in two virtual investor conferences: the Jefferies 2020 Virtual London Healthcare Conference from November 17-19, and the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3. Management will present at both events and will be available for one-on-one meetings. Aligos focuses on developing novel therapeutics for viral infections and liver diseases, aiming to advance targeted antiviral therapies.
Aligos Therapeutics (Nasdaq: ALGS) has announced that its Belgian subsidiary, Aligos Belgium BV, received a €1.8M grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project on combination therapy for Chronic Hepatitis B (CHB). This three-year project, named CoHeBA, aims to explore the therapeutic candidates' mechanisms and involves collaborations with leading laboratories globally. Aligos CEO Lawrence Blatt expressed optimism that project outcomes will enhance their therapeutic developments for CHB, which affects over 290 million people worldwide.